Multicenter Study Evaluating Regorafenib Versus Standard Care for Recurrent Meningioma
Led by Istituto Oncologico Veneto IRCCS · Updated on 2026-09-30
104
Participants Needed
20
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether Regorafenib can show antitumor activity against recurrent meningiomas, a type of malignant brain tumor. Previous small studies suggest that VEGF inhibitors may help control tumor growth, and Regorafenib targets several receptors and signaling pathways involved in meningioma development. It has shown promising activity in laboratory and animal studies and has been effective in other cancers, maintaining quality of life.
Participants will be randomly assigned to receive either Regorafenib tablets orally at 160 mg daily for 3 weeks followed by 1 week off, continuing until disease progression or unacceptable side effects, or to receive the local standard of care treatment as determined by their site. This is a multicenter, Phase II study comparing these two approaches in patients with recurrent meningioma.
During the study, participants will have regular assessments including MRI scans to monitor tumor progression, laboratory tests to check organ function, and evaluations of symptoms and quality of life. Researchers will measure progression-free survival over up to 54 months as the primary outcome, along with overall survival, response rate, patient-reported outcomes, toxicity, and disease control rate up to 42 months. The study will continue until March 2029.
CONDITIONS
Brief Title
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
Research Team
G
Gian Luca De Salvo, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Subject must understand and voluntarily sign informed consent before any study procedures
Able to take oral medication
Willing and able to follow study visit schedule and requirements
Histological diagnosis of meningioma per WHO 2021 classification
Radiological progression of tumor with planar growth >25% in last 12 months or new lesions
Not eligible for further surgery or radiotherapy
At least one measurable lesion (≥10 x 10 mm) on baseline MRI
ECOG performance status 0 to 1 (or Karnofsky ≥70)
Male or female aged 18 years or older
Life expectancy of at least 6 months
Available paraffin-embedded tumor tissue
Dexamethasone or equivalent steroid dose ≤4 mg/day within 7 days prior to randomization
Stable or decreasing steroid dosage for 7 days before randomization
Adequate cardiac, liver, renal, and hematological function
Specific laboratory values within defined limits at screening
For women of childbearing potential: agreement to use adequate contraception during treatment and 6 months after last dose
For male partners of premenopausal women: agreement to use barrier contraception during treatment and 6 months after last dose
Participants with controlled type I diabetes, hypothyroidism on replacement, or certain stable skin disorders allowed
Patients with measurable progressive meningioma after radiation therapy eligible if progression is at least 24 weeks post-radiation
Possible prior bevacizumab use for radionecrosis allowed under specified conditions
You will not qualify if you...
Prior antineoplastic therapy for meningioma
Unable to understand or voluntarily sign informed consent
Taking strong CYP3A4 inhibitors or inducers
Taking strong UGT1A9 inhibitors
Receiving other active meningioma treatments outside the trial
Disease outside the brain (e.g., spinal cord, bone, distant metastasis)
Candidate for urgent palliative intervention for primary disease
History of allergy or hypersensitivity to study treatments or excipients
INR, PT, or aPTT not within therapeutic limits if anticoagulation intended
Unable or unwilling to undergo brain MRI with IV gadolinium
History of other malignancy within past 3 years except in situ or certain skin cancers
Serious non-healing wounds, ulcers, fractures, or abscesses
Cerebrovascular accident within last 6 months
Ongoing infection grade 2 or higher
Significant bleeding events within 4 weeks before study
Uncontrolled or severe cardiac disease
History of interstitial lung disease or related conditions
Active or suspected autoimmune disease
Known hepatitis B, active hepatitis C, or HIV requiring treatment
History of bleeding disorders
Uncontrolled intercurrent illness
Persistent grade 3 or higher lipase elevation
Persistent proteinuria ≥3.5 g/24 hours
Any malabsorption condition
Conditions impairing compliance with study procedures as judged by investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Until disease progression or unacceptable toxicity
Participants receive either Regorafenib tablets daily for 3 weeks followed by 1 week off, or the local standard of care treatment, continuing until disease progression or unacceptable side effects.
Regular visits for monitoring and assessments
Follow-up
Duration - Up to 54 months
Participants are monitored for tumor progression, survival, side effects, and quality of life through regular assessments.
Periodic visits for outcome measurements
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Pilot Trial of Hypofractionated Stereotactic Radiosurgery After Surgery for Intermediate-risk Meningioma Evaluating Safety and Outcomes
Multicenter Study Evaluating Regorafenib Versus Standard Care for Recurrent Meningioma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).